Does losing weight seem out of reach?

Overview

If you’re struggling to lose weight on your own, talk to your doctor about the SURMOUNT-3 Study
Beyond a potential new investigational weight management option, study participants will also receive counseling and support to make healthier choices. Obesity is a chronic disease and its increasing prevalence is a public health concern associated with rising incidence of Type 2 diabetes mellitus (T2DM), increased risk for premature death, and increased risk for some cancers.

Ages

18 and over

Study Topics

Obesity

Logo Lilly

Application for Current Clinical Research Study

* indicates required
() - (###) ###-####
Best Time to Reach You
Optin

Obesity Resources

  • The US obesity prevalence was 42.4% in 2017 – 2018.
  • From 1999 –2000 through 2017 –2018, US obesity prevalence increased from 30.5% to 42.4%. During the same time, the prevalence of severe obesity increased from 4.7% to 9.2%.
  • Obesity-related conditions include heart disease, stroke, type 2 diabetes, and certain types of cancer. These are among the leading causes of preventable, premature death.
  • The estimated annual medical cost of l icon in the United States was $147 billion in 2008. Medical costs for people who had obesity was $1,429 higher than medical costs for people with a healthy weight.
Source: https://www.cdc.gov/obesity/data/adult.html

About the SURMOUNT-3 Study

This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.

This research study is enrolling people who:

Are you 18 and over

Have BMI greater than 30

History of at least 1 self-reported unsuccessful dietary effort to lose body weight

Have not Type 1 and 2 diabetes